Amended Statement of Ownership (sc 13g/a)
January 25 2018 - 5:05PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment No. 1 – Exit Filing)*
PROTALIX BIOTHERAPEUTICS,
INC.
(Name
of Issuer)
Common
Stock, par value $0.001 per share
|
(Title
of Class of Securities)
(CUSIP
Number)
Mr. Yossi Maimon,
Chief Financial Officer
2 Snunit Street,
Science Park, POB 455, Carmiel 20100, Israel
972-4-988-9488
(Name,
Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
December 31,
2017
(Date
of Event which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
o
Rule 13d-1(b)
x
Rule 13d-1(c)
o
Rule 13d-1(d)
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.
The information
required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
CUSIP No. 74365A101
|
|
13G
|
|
Page 2 of 5 Pages
|
|
|
|
|
|
1.
|
|
NAMES
OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Abir Therapeutics Ltd
|
|
|
2.
|
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)
o
(b)
o
|
|
|
3.
|
|
SEC
USE ONLY
|
|
|
4.
|
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Israel
|
|
|
|
|
|
|
|
NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
|
5.
|
|
SOLE
VOTING POWER
0
|
|
6.
|
|
SHARED
VOTING POWER
0
|
|
7.
|
|
SOLE
DISPOSITIVE POWER
0
|
|
8.
|
|
SHARED
DISPOSITIVE POWER
0
|
|
|
|
|
|
9.
|
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
|
|
|
10.
|
|
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)
o
|
|
|
11.
|
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0%
|
|
|
12.
|
|
TYPE
OF REPORTING PERSON (see instructions)
CO
|
|
|
|
|
|
|
|
|
|
|
|
|
CUSIP No. 74365A101
|
|
13G
|
|
Page 3 of 5 Pages
|
|
|
|
|
|
Item 1.
|
(a)
|
Name of Issuer
Protalix BioTherapeutics, Inc.
|
|
|
|
|
(b)
|
Address
of Issuer’s Principal Executive Offices
2 Snunit Street, Science Park, POB 455, Carmiel 20100, Israel
|
|
|
|
Item 2.
|
(a)
|
Name of Person Filing
Abir Therapeutics Ltd
|
|
|
|
|
(b)
|
Address of the Principal Office or, if
none, residence
Amot Investment Tower, 2 Weizmann St. P.O. Box 33123, Tel Aviv, 64239 Isreal
|
|
|
|
|
(c)
|
Citizenship
Israel
|
|
|
|
|
(d)
|
Title of Class of Securities
Common Stock, par value $0.001 per share
|
|
|
|
|
(e)
|
CUSIP Number
74365A101
|
|
|
|
Item 3. If
this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
|
(a)
|
o
|
Broker or dealer registered
under section 15 of the Act (15 U.S.C. 78o).
|
|
|
|
|
|
(b)
|
o
|
Bank as defined in section 3(a)(6) of the
Act (15 U.S.C. 78c).
|
|
|
|
|
|
(c)
|
o
|
Insurance company as defined in section
3(a)(19) of the Act (15 U.S.C. 78c).
|
|
|
|
|
|
(d)
|
o
|
Investment company registered under section
8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
|
|
|
|
|
|
(e)
|
o
|
An investment adviser in accordance with
§240.13d-1(b)(1)(ii)(E);
|
|
|
|
|
|
(f)
|
o
|
An employee benefit plan or endowment fund
in accordance with §240.13d-1(b)(1)(ii)(F);
|
|
|
|
|
|
(g)
|
o
|
A parent holding company or control person
in accordance with §240.13d-1(b)(1)(ii)(G);
|
|
|
|
|
|
(h)
|
o
|
A savings associations as defined in Section
3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
|
|
|
|
|
(i)
|
o
|
A church plan that is excluded from the
definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
|
|
|
|
|
(j)
|
o
|
Group, in accordance with §240.13d-1(b)(1)(ii)(J).
|
|
|
|
|
|
CUSIP No. 74365A101
|
|
13G
|
|
Page 4 of 5 Pages
|
Item 4. Ownership.
Provide the
following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item
1.
|
|
|
|
|
|
(a)
|
|
Amount beneficially owned: 0
|
|
|
|
|
|
|
(b)
|
|
Percent of class: 0%
|
|
|
|
|
|
|
(c)
|
|
Number of shares as to which
the person has: 0
|
|
|
|
|
|
|
|
|
(i)
|
Sole power to vote or to direct the vote 0
|
|
|
|
|
|
|
|
|
(ii)
|
Shared power to vote or to direct the vote 0
|
|
|
|
|
|
|
|
|
(iii)
|
Sole power to dispose or to direct the
disposition of 0
|
|
|
|
|
|
|
|
|
(iv)
|
Shared power to dispose or to direct the
disposition of 0
|
|
|
|
|
|
Instruction
.
For computations regarding securities which represent a right to acquire an underlying security
see
§240.13d-3(d)(1).
Item 5. Ownership
of Five Percent or Less of a Class.
If
this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check the following
x
Instruction
.
Dissolution of a group requires a response to this item.
Item 6. Ownership
of More than Five Percent on Behalf of Another Person.
Not applicable
Item 7. Identification
and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
Not applicable
Item 8. Identification
and Classification of Members of the Group.
Not applicable
Item 9. Notice
of Dissolution of Group.
Not applicable
|
|
|
|
|
CUSIP No. 74365A101
|
|
13G
|
|
Page 5 of 5 Pages
|
Item 10. Certification.
|
|
|
|
|
(a)
|
|
The following certification
shall be included if the statement is filed pursuant to §240.13d-1(b):
|
|
|
|
|
|
|
|
|
By signing below I certify that, to the
best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business
and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction
having that purpose or effect.
|
|
|
|
|
|
|
|
(b)
|
|
The following certification
shall be included if the statement is filed pursuant to §240.13d-1(c):
|
|
|
|
|
|
|
|
|
By signing below I certify that, to the
best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or
with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held
in connection with or as a participant in any transaction having that purpose or effect.
|
|
|
|
|
|
|
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
01/25/2018
|
|
Date
|
|
|
|
/s/ Jonathan
Goodman
|
|
Signature
|
|
|
|
Jonathan Goodman,
Director
|
|
Name/Title
|
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Sep 2023 to Sep 2024